

IRF-1 (H-8): sc-74530

BACKGROUND

Interferon regulatory factor-1 (IRF-1) and IRF-2 have been identified as novel DNA-binding factors that function as regulators of both type I interferon (interferon- α and β) and interferon-inducible genes. The two factors are structurally related, particularly in their N-terminal regions, which confer DNA binding specificity. In addition, both bind to the same sequence within the promoters of interferon- α and interferon- β genes. IRF-1 functions as an activator of interferon transcription, while IRF-2 binds to the same *cis* elements and represses IRF-1 action. IRF-1 and IRF-2 have been reported to act in a mutually antagonistic manner in regulating cell growth; overexpression of the repressor IRF-2 leads to cell transformation while concomitant overexpression of IRF-1 causes reversion. IRF-1 and IRF-2 are members of a larger family of DNA binding proteins that includes IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, ISGF-3 γ p48 (a component of the ISGF-3 complex) and IFN consensus sequence-binding protein (ICSBP).

CHROMOSOMAL LOCATION

Genetic locus: IRF1 (human) mapping to 5q31.1.

SOURCE

IRF-1 (H-8) is a mouse monoclonal antibody raised against amino acids 121-325 of IRF-1 of human origin.

PRODUCT

Each vial contains 200 μ g IgG κ light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin. Also available as TransCruz reagent for Gel Supershift and ChIP applications, sc-74530 X, 200 μ g/0.1 ml.

IRF-1 (H-8) is available conjugated to agarose (sc-74530 AC), 500 μ g/0.25 ml agarose in 1 ml, for IP; to HRP (sc-74530 HRP), 200 μ g/ml, for WB, IHC(P) and ELISA; to either phycoerythrin (sc-74530 PE), fluorescein (sc-74530 FITC), Alexa Fluor® 488 (sc-74530 AF488), Alexa Fluor® 546 (sc-74530 AF546), Alexa Fluor® 594 (sc-74530 AF594) or Alexa Fluor® 647 (sc-74530 AF647), 200 μ g/ml, for WB (RGB), IF, IHC(P) and FCM; and to either Alexa Fluor® 680 (sc-74530 AF680) or Alexa Fluor® 790 (sc-74530 AF790), 200 μ g/ml, for Near-Infrared (NIR) WB, IF and FCM.

Alexa Fluor® is a trademark of Molecular Probes, Inc., Oregon, USA

APPLICATIONS

IRF-1 (H-8) is recommended for detection of IRF-1 of human origin by Western Blotting (starting dilution 1:100, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for IRF-1 siRNA (h): sc-35706, IRF-1 shRNA Plasmid (h): sc-35706-SH and IRF-1 shRNA (h) Lentiviral Particles: sc-35706-V.

IRF-1 (H-8) X TransCruz antibody is recommended for Gel Supershift and ChIP applications.


Molecular Weight of IRF-1: 48 kDa.

Positive Controls: IRF-1 (h2): 293T Lysate: sc-159114, Jurkat whole cell lysate: sc-2204 or Raji whole cell lysate: sc-364236.


STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

DATA



IRF-1 (H-8): sc-74530. Western blot analysis of IRF-1 expression in non-transfected 293T: sc-117752 (A), human IRF-1 transfected 293T: sc-159114 (B) and Jurkat (C) whole cell lysates.



IRF-1 (H-8): sc-74530. Western blot analysis of IRF-1 expression in Raji whole cell lysate.

SELECT PRODUCT CITATIONS

1. la Sala, A., et al. 2009. Cholera toxin inhibits IL-12 production and CD8 α ⁺ dendritic cell differentiation by cAMP-mediated inhibition of IRF-8 function. *J. Exp. Med.* 206: 1227-1235.
2. Librechts, S.F., et al. 2011. Chronic IFN- γ production in mice induces anemia by reducing erythrocyte life span and inhibiting erythropoiesis through an IRF-1/PU.1 axis. *Blood* 118: 2578-2588.
3. Londhe, P., et al. 2012. CIITA is silenced by epigenetic mechanisms that prevent the recruitment of transactivating factors in rhabdomyosarcoma cells. *Int. J. Cancer* 131: E437-E448.
4. Zhang, P., et al. 2013. SAHA down-regulates the expression of indoleamine 2,3-dioxygenase via inhibition of the JAK/Stat1 signaling pathway in gallbladder carcinoma cells. *Oncol. Rep.* 29: 269-275.
5. Sgarbanti, M., et al. 2014. I κ B kinase ϵ targets interferon regulatory factor 1 in activated T lymphocytes. *Mol. Cell. Biol.* 34: 1054-1065.
6. Shi, L., et al. 2015. Endotoxin tolerance in monocytes can be mitigated by α 2-interferon. *J. Leukoc. Biol.* 98: 651-659.
7. Yuan, J., et al. 2019. MIR17HG-miR-18a/19a axis, regulated by interferon regulatory factor-1, promotes gastric cancer metastasis via Wnt/ β -catenin signalling. *Cell Death Dis.* 10: 454.
8. Tan, L., et al. 2020. Interferon regulatory factor-1 suppresses DNA damage response and reverses chemotherapy resistance by downregulating the expression of RAD51 in gastric cancer. *Am. J. Cancer Res.* 10: 1255-1270.
9. Wandel, M.P., et al. 2020. Guanylate-binding proteins convert cytosolic bacteria into caspase-4 signaling platforms. *Nat. Immunol.* 21: 880-891.
10. Chen, W., et al. 2021. Inhibition of GFAT1 in lung cancer cells destabilizes PD-L1 protein. *Carcinogenesis* 42: 1171-1178.

RESEARCH USE

For research use only, not for use in diagnostic procedures.